The Globally Rising Number Of Cancer Cases Drives Cancer Monoclonal Antibodies Industry
Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
The Business Research Company’s Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON , UK, April 20, 2021 /EINPresswire.com/ -- Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody therapy market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibodies market.
The cancer monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of cancer and related services by entities (organizations, sole traders and partnerships) that produce monoclonal antibodies for cancer treatment. Monoclonal antibodies are highly specific molecules for cancer cells as they bind to the proteins on their surface and it activates an immune response. The market consists of revenue generated by cancer monoclonal antibodies companies manufacturing cancer monoclonal antibodies drugs.
Read More On The Global Cancer Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change
The cancer monoclonal antibodies market covered in this report is segmented by monoclonal antibody therapies into bevacizumab (avastin), rituximab (rituxan), trastuzumab (herceptin), cetuximab (erbitux), panitumumab (vectibix), others, by application into breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, others, and by end user into hospitals and clinics, research laboratories, pharmacies, others.
The global cancer monoclonal antibodies market size is expected to grow from $45.51 billion in 2020 to $49.77 billion in 2021 at a compound annual growth rate (CAGR) of 9.4%. The cancer monoclonal antibodies market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer monoclonal antibodies market is expected to reach $69.96 billion in 2025 at a CAGR of 9%.
Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., and Spectrum Pharmaceuticals.
Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market overview, forecast cancer monoclonal antibodies market size and growth for the whole market, cancer monoclonal antibodies market segments, and geographies, cancer monoclonal antibodies market trends, cancer monoclonal antibodies market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Cancer Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3451&type=smp
Here Is A List Of Similar Reports By The Business Research Company:
Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/breast-cancer-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change
Global Biologics Market - By Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), By Route Of Administration (Oral, Others (IV or IP)), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription Drugs, OTC Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/biologics-market
Monoclonal Antibodies (MAbs) Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-mabs-global-market-report
Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/conjugated-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change
Oncology Drugs Market - By Type (Blood Cancer, Breast Cancer, Lung Cancer, Prostate cancer, Colorectal Cancer, Cervical cancer, Kidney cancer, Gastric Cancer, Brain Tumor, Skin Cancer, Ovarian Cancer, Bladder Cancer, Pancreatic Cancer, Thyroid cancer, Others), By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy, Hormonal Therapy), By Distribution Channel (Retail Pharmacies/Drug Stores, Hospital Pharmacies, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded, Generic), And By Region, Opportunities And Strategies - Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
CAR-T Therapy Market - By Target Antigen (CD19 Therapy, CD22 Therapy, BCMA Therapy, Others), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Others), And By Region, Opportunities And Strategies - Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/car-t-therapy-market
Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
